Tag - SYN

Synthetic Biologics Logo

Maxim starts Synthetic Biologics at buy; PT $1.50

Maxim Group initiated coverage of Synthetic Biologics (NYSE American:SYN) with a “buy” rating and price target of $1.50. The stock closed at 47 cents on June 17. The company is focused on the gut microbiome with two...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.